An observational study in Thyroid Cancer, sponsored by Grupo Espanol de Tumores Neuroendocrinos. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Grupo Espanol de Tumores Neuroendocrinos · Observational
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
This study's planned enrollment of 20 is below the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Browse Thyroid Neoplasms studies →Grupo Espanol de Tumores Neuroendocrinos is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hystopathological characteristics of the tumor
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Time frame: Baseline
Situation of the tumor at first-diagnosis
Local tumor, locoregional tumor or metastatic disease.
Time frame: Baseline
Tumor-Node-Metastasis classification
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time frame: Baseline
Tumor Stage
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Time frame: Baseline
Patient situation at the end of treatment
Results of clinical evaluation of the disease including complete response, partial response, stable disease, progression of disease or death
Time frame: 12 months
Number of patients with BRAF mutation
Total patients with available results on BRAF status and proportion of patients with mutated BRAF or native BRAF.
Time frame: 12 months
Number of patients with RET mutation
Total patients with available results on RET status and proportion of patients with mutated RET or native RET.
Time frame: 12 months
Number of patients with PI3K mutation
Total patients with available results on PI3K status and proportion of patients with mutated PI3K or native PI3K.
Time frame: 12 months
Number of patients with RAS mutation
Total patients with available results on RAS status and proportion of patients with mutated RAS or native RAS.
Time frame: 12 months
Number of patients with PAX8/PAR mutation
Total patients with available results on PAX8/PAR status and proportion of patients with mutated PAX8/PAR or native PAX8/PAR.
Time frame: 12 months
Number of patients with P53 mutation
Total patients with available results on P53 status and proportion of patients with mutated P53 or native P53.
Time frame: 12 months
Number of patients with PTEN mutation
Total patients with available results on PTEN status and proportion of patients with mutated PTEN or native PTEN.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2019 (actual). Primary completion is estimated for Dec 2028, 115 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Grupo Espanol de Tumores Neuroendocrinos